Safety Issues in Pre-exposure Prophylaxis for HIV Negative Individuals, Proposals for Management of Safety Concerns, and Pending Plans for Scale-up

August 19, 2011

Welcome and Introductions, Veronica Miller

Welcome – FDA, Debra Birnkrant, FDA

iPrEx Safety Review, Robert Grant, UCSF

USTDF-X/Botswana Safety Review, Lynn Paxton, CDC

Partners PrEP, Connie Celum, UW

Session 1: What are the safety issues of concern with pre-exposure prophylaxis?

Session 2: Remedies and their Pros and Cons

Session 3: Public Health Implications

Session 4: Next Steps

Session 5: Summary and Action Item